AR123999A1 - Método para la preparación de ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico cristalino y la composición farmacéutica que lo comprende - Google Patents
Método para la preparación de ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico cristalino y la composición farmacéutica que lo comprendeInfo
- Publication number
- AR123999A1 AR123999A1 ARP210103066A ARP210103066A AR123999A1 AR 123999 A1 AR123999 A1 AR 123999A1 AR P210103066 A ARP210103066 A AR P210103066A AR P210103066 A ARP210103066 A AR P210103066A AR 123999 A1 AR123999 A1 AR 123999A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- compound
- crystalline particles
- weight
- diseases
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- IMBBXSASDSZJSX-UHFFFAOYSA-N 4-Carboxypyrazole Chemical compound OC(=O)C=1C=NNC=1 IMBBXSASDSZJSX-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 239000002245 particle Substances 0.000 abstract 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 abstract 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 abstract 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 abstract 3
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 3
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 abstract 2
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 229940127557 pharmaceutical product Drugs 0.000 abstract 2
- 239000003826 tablet Substances 0.000 abstract 2
- JLQQRYOWGCIMMZ-UHFFFAOYSA-N 1-(3-cyano-1-propan-2-ylindol-5-yl)pyrazole-4-carboxylic acid Chemical compound C=1C=C2N(C(C)C)C=C(C#N)C2=CC=1N1C=C(C(O)=O)C=N1 JLQQRYOWGCIMMZ-UHFFFAOYSA-N 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 201000005569 Gout Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000012659 Joint disease Diseases 0.000 abstract 1
- 108010093894 Xanthine oxidase Proteins 0.000 abstract 1
- 102100033220 Xanthine oxidase Human genes 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000006835 compression Effects 0.000 abstract 1
- 238000007906 compression Methods 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 125000004494 ethyl ester group Chemical group 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 210000000936 intestine Anatomy 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 239000007935 oral tablet Substances 0.000 abstract 1
- 229940096978 oral tablet Drugs 0.000 abstract 1
- 239000008213 purified water Substances 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 abstract 1
- 238000005406 washing Methods 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a una composición farmacéutica que comprende partículas cristalinas que comprenden el compuesto de fórmula (1) o una sal farmacéuticamente aceptable del este que comprende el compuesto de fórmula (2), debajo, en una cantidad de 0,2% en peso o menos. Las partículas cristalinas según la presente invención, tienen un tamaño, una forma y una distribución que mejoran la uniformidad y la fluidez, además de estar optimizadas para su entrada en el proceso de preparación del producto farmacéutico acabado, lo que aumenta la uniformidad del contenido en el proceso de preparación del producto acabado y minimiza la rotura durante la compresión en comprimidos, y por lo tanto pueden utilizarse como materia prima farmacéutica adecuada para el proceso de preparación del producto farmacéutico acabado. Reivindicación 1: Una composición farmacéutica para el tratamiento o la prevención de enfermedades relacionadas con la xantina oxidasa seleccionadas del grupo que consiste en hiperuricacidemia, gota, insuficiencia cardíaca, enfermedades cardiovasculares, hipertensión, diabetes, enfermedades renales, enfermedades inflamatorias y articulares y enfermedades inflamatorias del intestino, que comprende partículas cristalinas del compuesto de fórmula (1), o un excipiente farmacéuticamente aceptable de este, que comprende el compuesto de fórmula (2) en una cantidad de 0,2% en peso o menos. Reivindicación 6: Un método para preparar partículas cristalinas de fórmula (1) que comprende el compuesto de fórmula (2) en una cantidad de 0,2% en peso o menos, que comprende las siguientes etapas: a) mezclar éster etílico de ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico, tetrahidrofurano y metanol al reactor y, luego, añadir lentamente NaOH y hacer reaccionar; b) añadir agua purificada y acetato de etilo; c) cristalizar mediante la adición gota a gota de HCl; y d) lavar y secar los cristales resultantes. Reivindicación 11: Un comprimido oral que comprende las partículas cristalinas de la reivindicación 10 como ingrediente farmacéutico activo (API), donde el contenido del API es del 20% al 70% en peso según el 100% en peso del comprimido total.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20200145750 | 2020-11-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR123999A1 true AR123999A1 (es) | 2023-02-01 |
Family
ID=81458100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210103066A AR123999A1 (es) | 2020-11-04 | 2021-11-04 | Método para la preparación de ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico cristalino y la composición farmacéutica que lo comprende |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240000750A1 (es) |
| EP (1) | EP4218755A4 (es) |
| JP (1) | JP2023548160A (es) |
| KR (1) | KR20220060488A (es) |
| CN (1) | CN116456979A (es) |
| AR (1) | AR123999A1 (es) |
| AU (1) | AU2021374260A1 (es) |
| CA (1) | CA3194595A1 (es) |
| CL (1) | CL2023001025A1 (es) |
| CO (1) | CO2023007110A2 (es) |
| MX (1) | MX2023004835A (es) |
| PE (1) | PE20240139A1 (es) |
| TW (1) | TW202336015A (es) |
| WO (1) | WO2022098057A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR124178A1 (es) * | 2020-12-01 | 2023-02-22 | Lg Chemical Ltd | Formulación compuesta para administración oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico y un proceso para su preparación |
| JP2023551524A (ja) * | 2020-12-01 | 2023-12-08 | エルジー・ケム・リミテッド | １－（３－シアノ－１－イソプロピル－インドール－５－イル）ピラゾール－４－カルボン酸を含む経口用製剤、およびその製造方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19602505A1 (de) * | 1996-01-25 | 1997-07-31 | Merck Patent Gmbh | 1-(Pyrazol-4-Indol-3-yl)-Piperidine |
| ES2431815T3 (es) * | 2007-04-11 | 2013-11-28 | Kissei Pharmaceutical Co., Ltd. | Derivado de (aza)indol y uso del mismo para fines médicos |
| TWI423962B (zh) * | 2009-10-07 | 2014-01-21 | Lg Life Sciences Ltd | 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物 |
| TWI548630B (zh) * | 2011-04-06 | 2016-09-11 | Ｌｇ生命科學有限公司 | １－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸結晶型及其製造方法 |
| KR20200145750A (ko) | 2019-06-19 | 2020-12-30 | 한국전자통신연구원 | 시공간 예측을 이용한 비디오 부/복호화 방법 및 장치 |
-
2021
- 2021-11-02 CA CA3194595A patent/CA3194595A1/en active Pending
- 2021-11-02 CN CN202180072645.4A patent/CN116456979A/zh active Pending
- 2021-11-02 TW TW112120157A patent/TW202336015A/zh unknown
- 2021-11-02 KR KR1020210148950A patent/KR20220060488A/ko not_active Application Discontinuation
- 2021-11-02 US US18/251,646 patent/US20240000750A1/en active Pending
- 2021-11-02 PE PE2023001502A patent/PE20240139A1/es unknown
- 2021-11-02 AU AU2021374260A patent/AU2021374260A1/en active Pending
- 2021-11-02 MX MX2023004835A patent/MX2023004835A/es unknown
- 2021-11-02 EP EP21889522.5A patent/EP4218755A4/en active Pending
- 2021-11-02 JP JP2023526427A patent/JP2023548160A/ja active Pending
- 2021-11-02 WO PCT/KR2021/015708 patent/WO2022098057A1/ko active Application Filing
- 2021-11-04 AR ARP210103066A patent/AR123999A1/es unknown
-
2023
- 2023-04-10 CL CL2023001025A patent/CL2023001025A1/es unknown
- 2023-05-30 CO CONC2023/0007110A patent/CO2023007110A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022098057A1 (ko) | 2022-05-12 |
| TW202225158A (zh) | 2022-07-01 |
| CN116456979A (zh) | 2023-07-18 |
| EP4218755A4 (en) | 2024-03-27 |
| AU2021374260A1 (en) | 2023-06-01 |
| CL2023001025A1 (es) | 2023-12-11 |
| US20240000750A1 (en) | 2024-01-04 |
| KR20220060488A (ko) | 2022-05-11 |
| CO2023007110A2 (es) | 2023-07-10 |
| PE20240139A1 (es) | 2024-01-30 |
| CA3194595A1 (en) | 2022-05-12 |
| TW202336015A (zh) | 2023-09-16 |
| EP4218755A1 (en) | 2023-08-02 |
| MX2023004835A (es) | 2023-05-10 |
| JP2023548160A (ja) | 2023-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR123999A1 (es) | Método para la preparación de ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico cristalino y la composición farmacéutica que lo comprende | |
| KR102322794B1 (ko) | 핵수송 조절인자 및 이의 용도 | |
| TW523503B (en) | Retinoic acid mimetic anilides | |
| TWI657826B (zh) | Complex of angiotensin II receptor antagonist metabolite and NEP inhibitor and preparation method thereof | |
| DE60221804T2 (de) | Benzimidazolderivate zur ige-modulierung und zellproliferationshemmung | |
| WO2013017974A1 (en) | Compositions and methods for the treatment of neuromuscular disorders and neurodegenerative diseases | |
| CN106008488A (zh) | 氰基吲哚类衍生物及其制备方法和用途 | |
| CN104603096A (zh) | 用于治疗神经肌肉障碍和神经退行性疾病的组合物和方法 | |
| NO326465B1 (no) | Krystallinsk natriumsalt av Telmiseartan, fremgangsmate for fremstilling av slike, farmasoytiske formuleringer innholdende slike og dets anvendelse som legemiddel | |
| CN1028233C (zh) | 具有抑制胃酸作用的取代的苯并咪唑的制备方法 | |
| US20160362358A1 (en) | Compositions Comprising 15-oxo-EPA or 15-oxo-DGLA and Methods of Making and Using Same | |
| WO2014034626A1 (ja) | N-[2-({2-[(2S)-2-シアノピロリジン-1-イル]-2-オキソエチル}アミノ)-2-メチルプロピル]-2-メチルピラゾロ[1,5-a]ピリミジン-6-カルボキサミドの結晶 | |
| BR112019010809A2 (pt) | composto de fórmula i, composto de fórmula ii, composto de fórmula iii, composto de fórmula iv, composto de fórmula v, composto de fórmula vi, composto de fórmula vii, composto de fórmula viii, composto de fórmula ix, composto de fórmula x, composto de fórmula xi, composto de fórmula xii, e composição farmacêutica | |
| TW206205B (es) | ||
| CA2881182C (en) | Piperidinium quaternary salts | |
| JP2015533114A (ja) | 神経疾患の治療のための組成物及び方法 | |
| CN106187927B (zh) | 一种Lesinurad中间体的制备方法 | |
| CN110167548A (zh) | 用于治疗胃肠息肉的组合物和方法 | |
| KR102275045B1 (ko) | 모사프리드시트르산염수화물의 제조방법 및 이를 포함하는 약학제제 | |
| CN103772355A (zh) | 雷贝拉唑钠化合物 | |
| CA2935013A1 (en) | Pharmaceutical composition containing nitisinone, and its use | |
| AU2004295178A1 (en) | Therapeutics use of pyridinium compounds to modulate NAADP activity | |
| KR101076769B1 (ko) | 아미노산계 유도체를 포함하는 호흡기 질환의 예방, 개선 또는 치료하기 위한 의약 및 기능성 식품 조성물 | |
| CN103864755A (zh) | 一种雷贝拉唑钠化合物 | |
| CN107501255B (zh) | 一种艾沙康唑衍生物及其用途 |